RxDoctor Payments Data

Jennifer Pallone, DO

Psychiatry · Merrillville, INNPI 1295888923

Payments from drug & device makers

$5,467in general payments, 2019–2025

Across 256 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$829
  • Teva Pharmaceuticals USA, Inc.$650
  • Medtronic$394
  • Neurocrine Biosciences, Inc.$348
  • Acorda Therapeutics, Inc$258
  • Acadia Pharmaceuticals Inc$247
  • plus $3K from 40 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$5,444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,467 in reported general payments places this provider in the 85th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$240,926
Medicare patients
211
Services billed
21,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl60$204,514
NuplazidPimavanserin Tartrate29$194,684
IngrezzaValbenazine Tosylate11$83,572
RytaryCarbidopa/Levodopa32$66,678
BotoxOnabotulinumtoxina49$62,424
NeuproRotigotine11$27,640
NourianzIstradefylline13$25,033
Carbidopa-LevodopaCarbidopa/Levodopa379$12,016
XeominIncobotulinumtoxina15$10,412
Rivastigmine33$8,612
RivastigmineRivastigmine Tartrate95$7,465
Rasagiline Mesylate47$5,553
Ropinirole ErRopinirole Hcl23$5,545
Primidone123$3,941
AmantadineAmantadine Hcl65$3,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$224$204,51460 claims
Acadia Pharmaceuticals IncNuplazid$247$194,68429 claims
Neurocrine Biosciences, Inc.Ingrezza$348$83,57211 claims
Amneal Pharmaceuticals LLCRytary$166$66,67832 claims
AbbVieBotox$829$62,42449 claims
UCB, Inc.Neupro$34$27,64011 claims
Kyowa Kirin, Inc.Nourianz$156$25,03313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →